Toshiba America Medical Systems, Inc. announced the appointed of Aaron Hudy as vice president of sales at a time when the company is experiencing a strong growth trend in the diagnostic imaging industry.
Hudy, who has been with the company since 2002, will oversee field sales, strategic accounts and the company’s dealer and distributor organizations. “Aaron Hudy’s proven sales experience and extensive knowledge of both Toshiba and the industry will make him a valuable contributor to the strategic direction of the company,” said Larry Dentice, general manager and senior vice president, Toshiba.
Related Content
News | Computed Tomography (CT)
March 31, 2023 — Philips, a global leader in health technology, and Connally Memorial Medical Center (CMMC), today ...
March 31, 2023 
March 30, 2023 — GenesisCare, one of the leading integrated cancer care providers in the United States, Australia, Spain ...
March 30, 2023 
News | Radiology Business
March 27, 2023 — Swissray brand has a long history of pioneering digital x-ray technology. One of the first markets that ...
March 27, 2023 
News | Nuclear Imaging
March 22, 2023 — A novel imaging modality that can visualize the distribution of medical radiopharmaceuticals with very ...
March 22, 2023 
News | Lung Imaging
March 22, 2023 — The Riverain Technologies ClearRead Bone Suppression solution is now available on the Siemens ...
March 22, 2023 
News | Digital Pathology
March 21, 2023 — Pramana, Inc., an AI-enabled health tech company modernizing the pathology sector, and PathPresenter ...
March 21, 2023 
News | Radiology Business
March 21, 2023 — Boston Imaging, a subsidiary of Samsung Electronics, Co. Ltd, appoints Eric Sumner as the new Digital ...
March 21, 2023 
News | Digital Radiography (DR)
March 20, 2023 — A study by Emory Healthcare reports that Konica Minolta Healthcare’s Dynamic Digital Radiography (DDR) ...
March 20, 2023 
News | X-Ray
March 20, 2023 — Researchers from UNSW Sydney have developed an algorithm which produces high-resolution modeled images ...
March 20, 2023 ![A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to treat metastatic prostate cancer, has led to shortages resulting in a delay of 3 months or longer for new patients](/sites/default/files/styles/feed_medium/public/Screen%20Shot%202023-03-16%20at%201.46.39%20PM.png?itok=a2-uUeQz)
March 16, 2023 — A supply problem with Pluvicto [177Lu-vipivotide tetraxetan; Novartis], the radiopharmaceutical used to ...
March 16, 2023 © Copyright Wainscot Media. All Rights Reserved.
Subscribe Now